Background: The molecular mechanisms associated with thoracic aortic dissection (TAD) remain poorly understood. A comprehensive high-throughput sequencing-based analysis of the circRNA–miRNA–mRNA competitive endogenous RNA (ceRNA) regulatory network in TAD has not been conducted. The purpose of this study is to identify and verify the key ceRNA networks which may have crucial biological functions in the pathogenesis of TAD. Methods: Gene expression profiles of the GSE97745, GSE98770, and GSE52093 datasets were acquired from the Gene Expression Omnibus (GEO) database. Differentially expressed genes (DEGs) were identified using the GEO2R tools. Protein–protein interaction (PPI) networks of the hub genes were constructed using STRING; the hub genes and modules were identified by MCODE and CytoHubba plugins of the Cytoscape. We analyzed the hub genes using Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis. The functions of these hub genes were assessed using Cytoscape software. Our data—along with data from GSE97745, GSE98770, and GSE52093—were used to verify the findings. Results: Upon combined biological prediction, a total of 11 ce-circRNAs, 11 ce-miRNAs, and 26 ce-mRNAs were screened to construct a circRNA–miRNA–mRNA ceRNA network. PPI network and module analysis identified four hub nodes, including IGF1R, JAK2, CSF1, and GAB1. Genes associated with the Ras and PI3K-Akt signaling pathways were clustered in the four hub node modules in TAD. The node degrees were most significant for IGF1R, which were also the most significant in the two modules (up module and hub module). IGF1R was selected as a key gene, and the hsa_circ_0007386/miR-1271–5P/IGF1R/AKT regulatory axis was established. The relative expression levels of the regulatory axis members were confirmed by RT-PCR in 12 samples, including TAD tissues and normal tissues. Downregulation of IGF1R expression in smooth muscle cells (SMCs) was found to induce apoptosis by regulating the AKT levels. In addition, IGF1R showed high diagnostic efficacy in both AD tissue and blood samples. Conclusions: The hsa_circ_0007386/miR-1271-5P/IGF1R/AKT axis may aggravate the progression of TAD by inducing VSMCs apoptosis. CeRNA networks could provide new insights into the underlying molecular mechanisms of TAD. In addition, IGF1R showed high diagnostic efficacy in both tissue and plasma samples in TAD, which can be considered as a diagnostic marker for TAD.
Objectives: The objective of this study was to evaluate the real-world efficacy of minimally invasive revascularization in diabetic foot ischemia, focusing on novel insights into device selection and lesion-specific predictors. Methods: This retrospective study included 98 patients (101 limbs) undergoing endovascular/hybrid interventions. The primary endpoints were 1- and 2-year primary patency and freedom from clinically driven target lesion revascularization (CD-TLR). Multivariate Cox regression identified restenosis predictors, with subgroup analysis comparing drug-coated devices (DCDs) versus conventional strategies in chronic limb-threatening ischemia (CLTI). Results: The cohort (mean age 72.1 ± 8.9 years) comprised 51% CLTI limbs (28.5% with tissue loss). The overall 1-year primary patency was 75.6%, declining to 67.6% after 2 years. The rates of freedom from CD-TLR were 87.4% after 1 year and 74.8% after 2 years. CLTI was associated with significantly reduced 1-year (66.5% vs. 84.9%) and 2-year primary patency (56.3% vs. 80.1%; log-rank p = 0.026) compared to non-CLTI. Multivariate analysis identified CLTI as an independent predictor of restenosis (HR 3.375, 95%CI 1.267–8.990, p = 0.015). Although DCDs did not improve 2-year primary patency in CLTI (58.5% vs. 57.3%, p = 0.768), they demonstrated superior 2-year CD-TLR-free survival (78.5% vs. 54.6%, p = 0.048). The total complication rate was 5.9%, with no significant difference between CLTI and non-CLTI groups (11.5% vs. 0%, p = 0.057). Conclusions: This study highlights CLTI’s impact on revascularization durability and the clinical benefits of DCDs in reducing reinterventions, offering evidence-based insights for tailored device selection despite retrospective limitations.
Objective: Endovascular recanalization is the preferred treatment for peripheral vascular diseases. This study evaluated the short-term outcomes of endovascular therapy for transplant renal artery stenosis (TRAS) administered based on anatomical foundations and three-dimensional digital subtraction angiography (3D-DSA). Methods: Patients with TRAS treated with endovascular therapy at a single center between October 2022 and October 2023 were retrospectively analyzed. The primary endpoint was the 12-month primary patency rate, defined as uninterrupted vessel patency without reintervention. Secondary endpoints included secondary patency rate (patency maintained after reintervention), blood pressure, and serum creatinine (Scr) levels. Results: The study included 23 patients (mean age: 41.1 ± 11.5 years; 9 females). All patients underwent successful plain old balloon angioplasty (POBA); 13 underwent POBA plus balloon-expandable bare-metal stent (BMS) deployment. The procedure-related complication rate was 13.04%. Technical success was defined as <30% residual stenosis with restoration of antegrade flow at completion angiography and was achieved in all cases (100%). The median follow-up was 14.9 ± 2.3 months (range11–19 months). The 12-month primary and secondary patency rates were 86.96% and 100%, respectively. The primary patency rates significantly differed between the POBA + BMS (100%) and POBA-only (70%) groups (P = 0.032). The systolic and diastolic blood pressure, pulse pressure, and Scr levels significantly differed pre- and post-operatively. No stent-related complications occurred. Conclusions: Endovascular treatment of TRAS based on anatomical foundations and 3D-DSA is safe and effective with a high patency rate. POBA with BMS might be a better solution.
5 May 2026 in European Journal of Medical Research
This study examined cellular composition, transcriptional patterns, and communication networks to develop therapeutic targets. We analyzed single-cell RNA-
Background/Objectives: Rates of postoperative recurrence of varicose veins range from 7% to 62%. We analyzed factors associated with recurrent varicose veins (RVVs) of the lower extremities after interventional treatment. Methods: We enrolled 99 patients (114 lower extremities) with RVVs admitted from January 2018 to June 2025 (71 women, 76 limbs; 28 men, 31 limbs; average age (SD) 63.9 (9.8) years). Duplex ultrasound scanning, magnetic resonance venography, or computed tomography venography were performed. The presence of a residual great saphenous vein, primary deep venous valve insufficiency, incompetent perforating veins, and iliac vein stenosis were recorded. We analyzed the charts of patients who underwent operations for recurrent varicose veins for associated factors. Results: We recorded residual trunk of the great saphenous vein in 55 limbs (48.3%), deep venous valve insufficiency in 47 (41.2%), incompetent perforating veins in 7 (6.1%), anterior accessory saphenous vein insufficiency in 2 (1.8%), and small saphenous vein insufficiency in 2 (1.8%). Iliofemoral venography indicated 31 limbs (27.2%; left lower, 24; right lower, 7) with a nonthrombotic iliac vein compression lesion. After identifying associated factors, retreatments—high ligation and stripping of the great saphenous vein or iliac vein stent implantation or small saphenous vein dissection ligation and stripping—were performed. The venous clinical severity score was 7 (interquartile range, 5–10) on admission and 3 (interquartile range, 2–4) 3 months after discharge.Conclusions: RVVs are associated with multiple factors, including inadequate initial surgical techniques, nonthrombotic iliac vein compression lesions, deep venous valve insufficiency, small saphenous vein insufficiency, and incompetent perforating veins. Performing detailed imaging before retreatment is essential to identify factors associated with RVVs and prevent recurrence.
Background: The reported postoperative recurrence rates of lower limb varicose veins differ considerably across studies, ranging from 7% to 62%. This study aimed to characterize the clinical and imaging findings in patients presenting with recurrent varicose veins (RVVs) and to describe short-term clinical outcomes after individualized reintervention. Methods: We enrolled 99 patients (114 lower extremities) with RVVs admitted from January 2018 to June 2025. All patients underwent duplex ultrasound scanning; computed tomography venography or magnetic resonance venography was performed to assess iliac vein anatomy. We analyzed the charts of patients for the prevalence of imaging and clinical abnormalities among patients with RVVs. This study was designed as a descriptive retrospective case series without a non-recurrent control group. We analyzed the distribution of venous abnormalities among the included limbs. Results: The mean patient age was 63.9 ± 9.8 years, and 71.7% of the patients were female. Among the 114 affected limbs, residual great saphenous vein trunks were identified in 55 (48.3%), deep venous reflux in 47 (41.2%), incompetent perforating veins in 7 (6.1%), anterior accessory great saphenous vein reflux in 2 (1.8%), and small saphenous vein reflux in 2 (1.8%). Iliac vein stenosis was suspected in 42 limbs, of which 38 underwent digital subtraction angiography; nonthrombotic iliac vein compression lesions were confirmed in 31 limbs. Confirmed lesions were more frequent in left-sided than right-sided RVVs limbs (35.8% vs. 16.3%; p = 0.03). The median venous clinical severity score decreased from 7 (interquartile range, 5–10) at admission to 2 (interquartile range, 2–3) 6 months after discharge (p < 0.01). All 20 active venous ulcers healed during follow-up. Conclusions: Residual great saphenous vein trunks, deep venous valve insufficiency, and nonthrombotic iliac vein compression lesions were frequently observed venous abnormalities in this retrospective descriptive case series of patients with RVVs. Comprehensive multimodal venous imaging may assist individualized reintervention planning. These findings describe a referred recurrent case series and cannot be interpreted as risk factors for recurrence without a non-recurrent control group. Long-term outcomes require further investigation.